Pharmaceutical management of ovarian cancer : current status.
about
Palliative surgery versus medical management for bowel obstruction in ovarian cancerPalliative surgery versus medical management for bowel obstruction in ovarian cancerAssessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group StudyThe effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinomaLovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevanceAn Example of Ovarian Cancer as a 'Chronic Disease Process' - 11-Year Survival with Multiple Treatments for Recurrent and Progressive DiseaseCurcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth.Quantitative imaging reveals heterogeneous growth dynamics and treatment-dependent residual tumor distributions in a three-dimensional ovarian cancer model.Synergistic enhancement of carboplatin efficacy with photodynamic therapy in a three-dimensional model for micrometastatic ovarian cancer.Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancerFeed forward artificial neural network: tool for early detection of ovarian cancer.Therapeutic advances in women's cancersExpression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer.Doublet chemotherapy in the elderly patient with ovarian cancer.RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.Distinct genetic alterations occur in ovarian tumor cells selected for combined resistance to carboplatin and docetaxelHigh efficacy of CpG-ODN, cetuximab and cisplatin combination for very advanced ovarian xenograft tumors.Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancerLongitudinal health-related quality of life assessment: implications for prognosis in ovarian cancerPhotoimmunotherapy and irradiance modulation reduce chemotherapy cycles and toxicity in a murine model for ovarian carcinomatosis: perspective and results.Targeting signaling pathways in epithelial ovarian cancer.Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancerMoving beyond VEGF for anti-angiogenesis strategies in gynecologic cancerMethylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies.Can the status of the breast and ovarian cancer susceptibility gene 1 product (BRCA1) predict response to taxane-based cancer therapy?Ovarian cancer update: lessons from morphology, molecules, and mice.Epithelial cell adhesion molecule aptamer functionalized PLGA-lecithin-curcumin-PEG nanoparticles for targeted drug delivery to human colorectal adenocarcinoma cells.First-line treatment of advanced ovarian cancer: current research and perspectives.Recent advances in drug delivery strategies for treatment of ovarian cancer.Curcumin and lung cancer--a review.Ovarian cancer targeted hyaluronic acid-based nanoparticle system for paclitaxel delivery to overcome drug resistance.Docetaxel inhibits the proliferation of non-small-cell lung cancer cells via upregulation of microRNA-7 expression.Aurora kinase inhibitor AZD1152 has an additional effect of platinum on a sequential application at the human ovarian cancer cell line SKOV3.Effect of platinum-containing chemotherapy on olfactory, gustatory, and hearing function in ovarian cancer patients.Functional p53 determines docetaxel sensitivity in prostate cancer cells.Effect of small interfering RNA transfection on FAK and DLC1 mRNA expression in OVCAR-3.Cyclin G1 regulates the outcome of taxane-induced mitotic checkpoint arrest.Comparison in purity and antitumor effect of brand and generic paclitaxel against human ovarian cancer cells by an in vitro experimental model.The Role of Angiogenesis in the Persistence of Chemoresistance in Epithelial Ovarian Cancer.Small interfering RNA-mediated silencing of heat shock protein 27 (HSP27) Increases chemosensitivity to paclitaxel by increasing production of reactive oxygen species in human ovarian cancer cells (HO8910).
P2860
Q24234043-5FAE0148-27DC-4466-9D54-DAA8D2BFDC81Q24240817-AC29D1AB-3858-4D08-9B93-AA222EDF015EQ30417640-775F7685-25BA-46BB-8493-D3006B47D5D2Q33514437-51092425-19CD-411A-967A-F098646FB502Q33542856-E2D9E811-6765-4BC3-A9CD-C5CC64D4AFA2Q33612533-9B5C66E4-CC82-4334-A834-9E1277B3E206Q33892483-9C714DCB-FC83-4606-AD65-3FBF53F11488Q34166300-0965AECA-37EB-4A4A-A53C-A3C38C6AA993Q34676773-4618B6E9-F10A-4732-BA46-8AA9D48F4231Q34711457-A3D27CF2-8DF7-48D8-8A63-FDE205ABDDCBQ35185305-CDE09C87-18C4-415E-A978-40DDDDB2A394Q35418973-FC5FD4F4-328C-42FD-8BF2-6D11D881A2B6Q35924210-70485F27-BB6C-421B-90EC-011D0E17CC7DQ36405668-770AA8F5-BC9B-424E-AF28-07CE59B8C49BQ36413165-64AB987C-813B-4CEB-A40D-068E9E1A81BDQ36521792-9E624E61-4DAB-4E0D-8B63-F103E8DB7924Q36608597-68F01994-1927-40B5-A01C-D81A07B5FE66Q36670959-116C06BB-310E-4765-859C-F0995C22D37CQ36694571-6F7AB904-A3DE-46F0-AAFA-78F958E2D006Q36790826-F9CB1E59-AC62-412F-BEBA-7F8035A78044Q36913614-21745140-543B-49C9-BE59-676A21B8FF2FQ36916243-021E8C1A-9C31-4029-97EE-EADE6B49E94DQ37086837-55335324-C609-4E3E-83E3-729EBCCF27FDQ37257390-36C14F0B-EAAA-4794-875F-249BE0F91C7AQ37349840-79BFE52C-8F08-4AC1-8947-5A931FF7D371Q37415611-635E522E-3E9B-461D-B834-1D1288F1E5FFQ37607750-A271595D-6458-452D-A065-2E1491DF75ACQ37656214-28646A89-DA35-40CE-B93F-51E7FDB87926Q37997512-ABB80331-4D81-47DF-9685-CA472FEC7771Q38212780-716AC87E-C2DD-4B4C-9B69-B8A1EDCDAA57Q38822371-0CB2B1C7-71CF-4EEC-BD2F-C65ECDE72AF3Q38828073-D02FBEB1-1E28-4F73-ACFC-76725BD28430Q39198408-19AE7750-C028-4257-8004-F63C42F9E805Q39249608-0BDB3B72-60B0-48BA-9BFB-D99EDCBE9866Q39274565-239A3121-A096-4EE7-92B2-F96E3DD2D3C7Q39320426-406F34DD-8B74-41EA-8E79-FB48266A4BC7Q39447537-1C21F397-2DA1-499F-BA5C-44C60D6DC56BQ39659161-E1B55F81-8EF8-43CF-B1FD-C1991C01E060Q39815570-C85BE3AD-1F29-49D1-8ABA-9E7D86C75D65Q43237439-E0632641-3956-4ADB-AEEE-23D73C9F4685
P2860
Pharmaceutical management of ovarian cancer : current status.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmaceutical management of ovarian cancer : current status.
@en
Pharmaceutical management of ovarian cancer : current status.
@nl
type
label
Pharmaceutical management of ovarian cancer : current status.
@en
Pharmaceutical management of ovarian cancer : current status.
@nl
prefLabel
Pharmaceutical management of ovarian cancer : current status.
@en
Pharmaceutical management of ovarian cancer : current status.
@nl
P1433
P1476
Pharmaceutical management of ovarian cancer : current status.
@en
P2093
Maurie Markman
P304
P356
10.2165/00003495-200868060-00004
P577
2008-01-01T00:00:00Z
P6179
1002089462